2013 Fiscal Year Final Research Report
A novel biomarker predicting the response to pegylated interferon-alpha plus ribavirin in patients with chronic hepatitis C
| Project/Area Number |
23590553
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Virology
|
|---|
| Research Institution | St. Marianna University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKUSE Chiaki 聖マリアンナ医科大学, 医学部, 准教授 (00318940)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | バイオマーカー / C型肝炎 / 血清ペプチド / 補体 / ペグインターフェロンα・リバビリン療法 |
|---|
| Research Abstract |
Novel biomarkers predicting sustained virological response (SVR) to pegylated interferon alpha plus ribavirin (PEG-IFNalpha/RBV) were investigated. Peptides in pretreatment sera from patients with hepatitis C virus (HCV) were comprehensively analyzed by mass spectrometry. In total, 107 peptides were detected in a training set (n=23). In all the responders (who achieved SVR) and the non-responders (n=96), sensitivity and specificity of SVR in a model consisting of ion intensity of 107 peptides, hemoglobin, BMI, and age were 70% and 92%, and those in another model consisting of ion intensity of complement 3f des-arginine (C3f-dR) and platelet count were 59% and 88%, respectively. Taken together, serum peptides, especially C3f-dR, would be useful predictors for SVR to PEG-IFNalpha/RBV. The complements may be involved in the HCV elimination.
|
